Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEDP -0.57%97 EV-to-EBITDA is 25.55 as of Aug. 03, 2026, which is 17% above its 10-year median of 21.80. GuruFocus rates MEDP with a GF Score™ of 97/100 and a GF Value™ of $530.65 (Fairly Valued). The stock has 2 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 69.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medpace Holdings's enterprise value is $15,619 Mil.
Medpace Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $611 Mil. Therefore, Medpace Holdings's EV-to-EBITDA for today is 25.55.
The historical rank and industry rank for Medpace Holdings's EV-to-EBITDA or its related term are showing as below:
MEDP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.83 Med: 21.8 Max: 46.72
Current: 25.55
During the past 13 years, the highest EV-to-EBITDA of Medpace Holdings was 46.72. The lowest was 10.83. And the median was 21.80.
MEDP's EV-to-EBITDA is ranked worse than 69.75% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.06
vs MEDP: 25.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medpace Holdings's PE Ratio (TTM) for today is calculated as:
Medpace Holdings's share price for today is $573.29.
Medpace Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medpace Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Medpace Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's EV-to-EBITDA falls into.
Medpace Holdings's current Enterprise Value is $15,619 Mil.
Medpace Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $611 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEDP) has a EV-to-EBITDA of 25.55 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medpace Holdings. This is 17% above median its historical median of 21.80. Over the past decade, Medpace Holdings' EV-to-EBITDA has ranged from 10.83 to 46.72. According to the industry distribution chart, Medpace Holdings ranks #83 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 69.7%.
Is Medpace Holdings' EV-to-EBITDA too high?
Medpace Holdings' current EV-to-EBITDA of 25.55 is 17% above median its 10-year median of 21.80. Over the past 10 years, this metric has ranged from a low of 10.83 to a high of 46.72. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.06. Medpace Holdings' value of 25.55 is 69.7% above this industry median. Based on the distribution chart, Medpace Holdings ranks #83 out of 119 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' EV-to-EBITDA compare to GH and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #83 out of 119 companies for EV-to-EBITDA. This places Medpace Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 15.06. Medpace Holdings' value of 25.55 is 69.7% above this benchmark. Historically, Medpace Holdings' own EV-to-EBITDA has ranged from 10.83 to 46.72 over the past decade. While the company's 10-year median is 21.80 vs. the industry median of 15.06, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.06, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current EV-to-EBITDA of 25.55 is 69.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medpace Holdings. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current EV-to-EBITDA is 25.55, which is 17% above median its own 10-year median of 21.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Fairly Valued. The stock's GF Value™ is $530.65, compared to a current price of $573.29 — trading 8% above its estimated fair value. The current EV-to-EBITDA is 25.55, which is 17% above median its 10-year median of 21.80 and 69.7% above the Medical Diagnostics & Research industry median of 15.06. Medpace Holdings' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current EV-to-EBITDA is 25.55 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of $573.29 is trading 8% above its estimated GF Value™ of $530.65.
GuruFocus considers Medpace Holdings to be Fairly Valued.
Key valuation signals for MEDP:
EV-to-EBITDA: 25.55 (17% above median its 10-year median of 21.80)
GF Value™: $530.65 vs. price of $573.29 (8% above fair value)
Industry Position: 69.7% above the Medical Diagnostics & Research median (#83 of 119)
No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score
Get the complete analysis for MEDP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDP has been successfully added to your 
